The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | KB707-02: inhaled KB707 for lung-related advanced solid tumors
Wen Wee Ma, MBBS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, safety and preliminary efficacy findings from the Phase I/II KB707-02 study (NCT06228326), evaluating inhaled KB707 monotherapy in patients with advanced solid tumors involving the lungs. KB707, a herpes simplex virus–based vector encoding IL-12 and IL-2, demonstrated a favorable safety profile with no severe treatment-related toxicities. The study has now expanded to assess combination strategies with pembrolizumab for non-small cell lung cancer. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have looked at about 30 or 40 patients and as I mentioned the treatment is given by inhalation and then we look at the side effects and the side effects are actually well tolerated. They are mild to moderate grade side effects and very transient so very well managed and what we also found is very encouragingly the hypothesis was proven that there was actually shrinkage of the tumors in the lungs...
We have looked at about 30 or 40 patients and as I mentioned the treatment is given by inhalation and then we look at the side effects and the side effects are actually well tolerated. They are mild to moderate grade side effects and very transient so very well managed and what we also found is very encouragingly the hypothesis was proven that there was actually shrinkage of the tumors in the lungs. So looking at that, what we are next step what we’re going to do is really then combine it with immune checkpoint inhibitor. So in this situation we have started combination with pembrolizumab and KB707 in patients with advanced non-small cell lung cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
